As Risperdal Goes Generic, Antipsychotics Seek To Differentiate Themselves
Executive Summary
Johnson & Johnson and other manufacturers of atypical antipsychotics face erosion of their market share with FDA's approval of the first generic version of J&J's Risperdal (risperidone). But they may ward off competition by emphasizing the differences between their products and the first generic among the newer antipsychotics
You may also be interested in...
Seroquel XR Needs Long-Term Safety Data For Depression, Anxiety Monotherapy – FDA Panel
AstraZeneca does gets recommendation for the atypical antipsychotic as adjunct therapy in major depressive disorder.
Teva Loses Exclusivity For Generic Risperdal; Mylan To Launch Its Product
Mylan is set to become the second generic manufacturer to launch a generic version of the antipsychotic drug Risperdal (risperidone), cutting short Teva's marketing exclusivity
Teva Loses Exclusivity For Generic Risperdal; Mylan To Launch Its Product
Mylan is set to become the second generic manufacturer to launch a generic version of the antipsychotic drug Risperdal (risperidone), cutting short Teva's marketing exclusivity